Page 1,147«..1020..1,1461,1471,1481,149..1,1601,170..»

From Animals to Human Society: What We Learn When Women Lead – Discover Magazine

Posted: February 8, 2020 at 4:50 pm

Theres something amiss with The Lion King aside from talking, singing animals. Disneys smash hit of stage and screen tells the tale of young male lion Simbas rise to power. But, in the real circle of life, lionesses lead.

Related females band together for life, as the primary hunters and warriors. Transient males join to mate but contribute little else to a prides success.

The lion queens, however, are an exception. Among mammal species that live in social groups, only about 10 percent have strong female leaders. They include another fierce predator, killer whales, as well as bonobos, famous for their peaceful promiscuity.

Humans, on the other hand, are part of the mammal majority: Our leaders are mostly male. Less than 7 percent of Fortune 500 CEOs are female. Worldwide, fewer than two dozen women are heads of state or government, including Germanys Angela Merkel and New Zealands Jacinda Ardern. In about 90 percent of nonindustrial societies studied by anthropologists, only men hold political posts.

Its undeniable that males have more sway across institutions, societies and mammal species. But what explains those lionesses, literal and figurative the females who lead? A multidisciplinary movement to study these outliers is gaining momentum. From hyena clans to corporate hiring culture, researchers are charting the pathways and barriers to female power among mammals, including our own species.

Bullies, warriors and wise matriarchsIn the dry, thorny forests of Madagascar, Verreauxs sifaka lemurs leap between trees with gravity-defying ease. For these primates, theres no question which sex is dominant.

Females beat up the males, says anthropologist Rebecca Lewis of the University of Texas at Austin. To avoid smacks to the face and bites, males call out submissively when females approach a chattering chi chi chi chi, which is the equivalent of bowing down, says Lewis. At trees laden with edible fruit, its ladies first: If a male climbs up, the feasting female may aggressively lunge or glare, and hell often retreat to the ground.

(Credit: Monika Hrdinova/Shutterstock)

But tensions escalate during the dry season, when food is so scarce the animals lose up to 20 percent of their weight. Theyre just really suffering during this time, says Lewis, who leads a wildlife research station in Madagascar.

One source of sustenance is the fatty baobab fruit. Its thick shell takes sifakas a half-hour to gouge open with their teeth. As a female works to free her own meal, she keeps an eye on nearby males. When one of them breaks open the shell, she claims the fruit like a schoolyard bully, slapping him to surrender.

He might even hold onto the fruit while shes eating just crying the whole time because he doesnt want to lose it, says Lewis.

Eventually he goes on to crack another. She takes that one, too.

During the dry season in Madagascar, baobab trees provide a crucial source of sustenance for Verreauxs sifaka lemurs: thick-shelled fruit. (Credit: Maxwell De Araujo Rodrigues/Dreamstime)

Few mammal females attain this degree of dominance defined by biologists as an animals ability to subordinate another through force or threat. Among the roughly 5,400 mammal species, in just a couple of dozen do females routinely outrank males during dominance contests. These include spotted hyenas and two types of naked mole rat, but lemur species make up the bulk of the list. For more than 20 species of lemurs, including Verreauxs sifaka, female rule is the rule, not the exception.

The fact that females are socially so powerful in [lemur] societies shows us that more traditional division of sex roles is not some inevitable destiny of mammalian biology, says Peter Kappeler, a zoologist at the University of Gttingen in Germany. That gives rise to all kinds of questions, why that might be the case, why lemurs are so different.

One obvious consideration is what Kappeler and others call the lemur syndrome: Females have traits that are typical of males in other mammal species. Their external genitalia are elongated, appearing more penislike, and their bodies are the same size or slightly larger than a males. With a mass difference of less than 10 percent, both sexes would belong to the same weight class in boxing. Lady lemurs also display so-called masculine behaviors: play tussling, marking territory with scent glands and intimidating subordinates with feigned or real cuffs and bites.

A similar pattern is found in African spotted hyenas: Females are larger and stronger, with masculinized vaginas and clitorises that resemble scrotums and penises. High-ranking females keep order in clans of up to 130 members, and comprise the front lines during wars against rival hyena clans or lions.

Not every social mammal species led by females has the same structure. For spotted hyenas, females are warriors that take on rival clans and lions. (Credit: S100apm/Dreamstime)

But body size and pseudo-penises arent enough to explain power dynamics in these species. Nor are hormones: Although pregnant hyenas and lemurs show elevated testosterone levels, most of the time adult females have lower concentrations than males a puzzling finding scientists are investigating.

A 2019 Nature Ecology and Evolution paper on spotted hyenas suggests that disproportionate social clout, rather than physical strength, fuels female dominance. Its authors analyzed 4,133 encounters between mixed or same-sex hyenas, which ended with one animal exerting dominance and the other retreating, cowering or otherwise signaling defeat. Over 75 percent of the time in all matchups, victory went to whichever animal had more potential allies close enough to call for backup. And, in spotted hyena society, high-ranking females have the most allies.

Another 2019 study, published in the International Journal of Primatology, looked at several hundred dominance contests between sifaka lemurs of varying ages. Although adult males bow down with the deferential chi chi chi chi to adult females, males of all ages get into conflicts with juvenile females. The researchers found juvenile females won about a quarter of the bouts and adolescents about half, regardless of body size. Adult females who had offspring past weaning age triumphed nearly 100 percent of the time. Sexual maturity and successful motherhood give these females status.

The findings challenge the idea that malelike traits gave rise to female dominance in these species. Perhaps female power, attained through social support or reproductive outcomes, led to lemur syndrome and its hyena equivalent.

Female orcas are among the few mammals that live decades past menopause, often leading their pods, especially in times of scarcity. (Credit: Ivkovich/Dreamstime)

Lewis, a co-author of the 2019 lemur study, has pushed researchers to look beyond physical dominance when investigating power relations. In her other articles, she contends that power ones ability to make another creature do something can be reached by alternate means or expressed in other ways.

Leadership is a special kind of power: influence over the entire group. Dominant animals can be leaders, capable of directing collective action. Or they may just be lone bullies at the baobab tree.

Strong female leadership is even more rare than female dominance among mammals. A 2018 study in Leadership Quarterly reviewed 76 social species in four decision-making contexts: collective travel, foraging and conflicts within or between groups. Defining leaders as individuals that routinely called the shots in at least two of these realms, the researchers identified eight species run by females: ruffed and ring-tailed lemurs, spotted hyenas, killer whales, African lions, bonobos and two types of elephant.

It looks like there are these independent evolutionary events where the set of circumstances gave rise to strong female leaders, says lead author Jennifer Smith, a biologist at Mills College.

For spotted hyenas and two lemur species, dominance certainly plays a role. But the other five species took different pathways to leadership. Female elephants and killer whales can live into their 80s in matrilineal societies, comprising up to four generations of mothers and offspring. With the most accumulated wisdom about local resources and dangers, female elders lead group movement and food pursuits. It makes so much incredible sense, says Smith. These long-lived females with great knowledge of course they should be the leaders.

In contrast to some species where physical dominance is the rule, peaceful bonobos form alliances. (Credit: Andrey Gudkov/Dreamstime)

Killer whales, or orcas, are also one of the few species in which females live decades past menopause. Orca communities especially follow these grandmothers (or great-grandmothers) during hard times, like when salmon prey are scarce, according to a 2015 study in Current Biology.

Meanwhile, female lions and bonobos derive strength from numbers. In both species, allied females fend off bigger, stronger males. Kinship unites the lionesses, but bonobos form coalitions of nonrelatives, which groom and fondle each other. Females of this chimpanzee species, through their cooperative social alliances, are in a way civically larger and more influential than one male, Smith explains.

Bias, biology and breaking through

Inthe 1970s, a review of historical descriptions of 93 nonindustrial societies found only about 10 percent permitted women to hold political posts and women were generally less powerful than male counterparts. Contemporary scholars attribute this in part to the mentality of past researchers: Ethnographers predominately men from Western patriarchies documented leadership in male-dominated domains like war, and overlooked female authority in economic, domestic and other spheres.

But even in more recent, less-biased research, it hits you in the face how disparately represented men and women are in positions of leadership, particularly more overt political leadership, says Christopher von Rueden, an anthropologist at the University of Richmonds Jepson School of Leadership Studies.

Consider the Tsimane, indigenous people of the Bolivian Amazon, who subsist on wild foods and garden-scale farming. Although Tsimane lack formal leaders, certain individuals have a greater voice in village affairs. In a 2018 Evolution and Human Behavior paper, von Rueden and colleagues found that, at community meetings, less than 10 percent of comments came from women. And when Tsimane ranked fellow villagers based on their ability to influence debates and manage projects, the average male score was higher than the scores of 89 percent of the women.

Among the Tsimane people of the Bolivian Amazon, political leadership is predominately, but not exclusively, male. Physical size, level of education and number of allies are factors in predicting political sway, and women do occasionally emerge as leaders in this nonindustrial society. (Credit: National Geographic Image Collection/Alamy)

And yet, consistent with global surveys, Tsimane political leadership is predominately but not exclusively male. Some women leaders exist among them.

Probing the data further, von Ruedens team found factors beyond a Y chromosome that predicted political sway, including a persons size, education and number of allies. The authors concluded that these qualities, rather than gender per se, elevated individuals to become leaders. It just so happens that Tsimane men generally place higher on those metrics than do women. For example, the female participants received, on average, 3.9 years of formal schooling, compared with 5.8 years for men. While physical differences are essentially set, gaps in education and social capital are not. Indeed, in another study of a more remote Tsimane village, the third-highest leader was a well-educated woman who had studied in a larger town.

Through his research, von Rueden seeks to explain how the evolution of sex differences affect access to leadership across human societies a topic fraught with potential land mines, he admits. Evolutionary anthropologists, including von Rueden, think the answer lies at the intersection of biological sex differences and the particular history, customs and environment of any given society.

Thanks to our mammalian roots, women bear and nurse babies. Men are generally larger and stronger just considering upper-body strength, 99 percent of women have less arm muscle mass than the average man. These biological realities set the stage for sexual division of labor, common across cultures. Men tended to take on riskier endeavors, like battles and big-game hunts, which require coalitions and hierarchical coordination. Tethered to children and homes, women assumed a greater share of domestic responsibilities, forming fewer but more intimate social ties.

From this evolutionary background, sex-based stereotypes emerged, which then became amplified or dampened by the particularities of a given society. For example, its been proposed that the invention of the plow deepened gender divisions because its use requires substantially more upper-body strength than hoe or stick tilling. This relegated men to fields and women to household labor. According to a 2013 Quarterly Journal of Economics study, the plows effects persist. The authors compared farming styles of more than 1,200 nonindustrial societies with gender beliefs of their modern descendants. The analysis found that descendants of plow-farmers have fewer women in the workforce and politics, and less-favorable views about gender equality. For example, in Pakistan, where earlier societies relied on the plow, only 16 percent of agricultural workers are women, compared with 90 percent in Burundi, which had traditional hoe tilling.

Understanding the evolution of male-skewed leadership, says von Rueden, puts us in a better position to act on behalf of putting more women in positions of power.

Theres a lot of catching up to do. In the U.S., while women make up half the entry-level workforce, their presence dwindles on each step of the corporate ladder, comprising just a quarter of senior managers, 11 percent of top earners and 5 percent of CEOs in S&P 500 companies, according to a 2019 report by Catalyst, a womens leadership nonprofit.

Based on metrics like wage gap, share of labor force and percentage of women working, gender equality rose beginning in the 1960s, peaked in the 90s and then stagnated for the past two decades.

Siri Chilazi, a fellow at the Women and Public Policy Program at Harvard University, says company policies and structures are part of the problem as are individual biases. For example, results of an experiment published in 2014 in the Proceedings of the National Academy of Sciences found that investors preferred entrepreneurial pitches from men, rating their presentations as more persuasive, logical, and fact-based than those from women. The catch: The content was identical, word for word.

Decades ago, major American symphonies changed their systems to blind auditions and saw significant increases in the number of women hired. (Credit: Stokkete/Dreamstime)

A now-classic analysis, published in 2000, underscores such biases. In the 1970s and 80s, major U.S. symphonies changed their auditions so musicians played behind a curtain that concealed their identity. Prior to the policy shift, less than 10 percent of new hires were women. Afterward, the number of female musicians in all orchestras increased exponentially most drastically for the New York Philharmonic, where, following the change, about 50 percent of new hires were women.

As Chilazi sees it, research has a clear message for organizations trying to level out gender ratios in leadership: Company policies are much easier to change and much easier to de-bias than our human brains.

Research runs thin when it comes to what is arguably the ultimate glass ceiling: elected national leadership. Starting in 1960 with Sri Lankas Prime Minister Sirimavo Bandaranaike, 115 women have served as president, prime minister or chancellor of 75 countries, from Brazil to Bangladesh. But, as in the business world, gender gains rose steeply through the 1990s and then recently reversed course.

The small number of women who have led their nations include Sri Lankas Sirimavo Bandaranaike (left) and Germanys Angela Merkel (right). (Credit: Elpisterra/Shutterstock; Everett Collection Historical/Alamy)

Oklahoma State University political scientist Farida Jalalzais research shows female executives tend to serve in systems with both a president and prime minister, often holding the weaker of the posts. Rather than popular vote, most are appointed by legislatures or winning parties, and into unstable posts that can be challenged. (Recall the no-confidence votes Theresa May faced in the U.K. Parliament.) Another factor: The majority hail from political families often the wives or daughters of former leaders.

Jalalzai notes that, while 2016 U.S. presidential candidate Hillary Clinton, the wife of a former president, fit this profile, the U.S.s presidency is a single, powerful head of state, rather than part of a power-sharing dual leadership system. The Oval Office is a tough glass ceiling to crack.

According to Jalalzai, although Clinton failed to win the presidency, the campaign may have shifted perceptions about who can assume the office. A record number of women entered the 2020 Democratic primary, for example. People didnt take her loss as the lesson that women shouldnt be competing for this, she says. It showed us, really, the opposite.

Jalalzai found similar effects globally, looking at public opinion surveys taken by 62,000 individuals from over 40 countries. In the 11 nations with female executives during the 2018 studys time frame, people were more accepting of female leaders, interested in politics and likely to vote, especially female respondents.

Other researchers have focused on local elections with corroborating results. In a 2018 Leadership Quarterly paper, researchers found that after the election of female mayors, those municipalities saw more women assuming top- and middle-management positions in public organizations. A study published in 2012 in Science considered the consequences of a 1993 Indian law that mandated that a random third of West Bengal villages reserve their chief councilor seat for an elected woman. Based on more than 8,400 surveys conducted in 495 villages, the researchers found that having a woman councilor for two election cycles improved aspirations for girls to pursue higher education and politics. The girls also spent more years in school and fewer minutes per day on domestic chores.

The studies suggest that, while gender equality does not beget female leaders, the reverse may be true: Women in high offices promote gender equality, either directly through policies and appointments, or indirectly by acting as a prominent reminder that women can lead.

Go here to read the rest:
From Animals to Human Society: What We Learn When Women Lead - Discover Magazine

Posted in Testosterone Shots | Comments Off on From Animals to Human Society: What We Learn When Women Lead – Discover Magazine

Tyson Fury is dipping his hands in petrol every day ahead of bout with Deontay Wilder – GIVEMESPORT

Posted: February 8, 2020 at 4:50 pm

Tyson Fury has revealed a bizarre new part of his training regime based on advice from the bare-knuckle boxing community.

'T'he Gypsy King', 31, is challenging for the WBC title for a second time against Deontay Wilder on February 22 after a controversial draw in the first bout between the pair.

Now, Fury has turned to his roots in the travelling community for advice to give him an edge in the next scheduled bout.

He told journalistGareth A Davies: I was speaking to an old legendary bare-knuckle fighter from the travelling community, hes called Big Joe Joyce.

He told me about dipping his hands in petrol, to toughen them up.

"So for this fight Ill be dipping my hands in petrol for five minutes a day during the last three or four weeks of the training camp to really toughen them up.

It worked for him, so Im going to give it a try.

This latest reveal comes a month after Fury admitted he would be masturbating seven times a dayahead of the fight to keep the testosterone pumping.

As far as training camps go, Fury's definitely sounds like one of the most unusual.

Fury largely out-boxed his opponent last time around, but it was 'The Bronze Bomber' who landed the power shots to put 'The Gypsy King' on the canvas twice during the fight.

It's pretty clear that Fury is looking for something to help him overcome the power of Wilder, who has won 41 of his 43 fights via knockout.

He'll be hoping that the combination of petrol soaked hands and masturbation helps him to victory later this month and sets up a potential unificationbout with Anthony Joshua in the near future.

Only time will tell if the unusual rituals work for Fury.

Go here to read the rest:
Tyson Fury is dipping his hands in petrol every day ahead of bout with Deontay Wilder - GIVEMESPORT

Posted in Testosterone Shots | Comments Off on Tyson Fury is dipping his hands in petrol every day ahead of bout with Deontay Wilder – GIVEMESPORT

Stopping Smoking Allows Healthy Lung Cells to Proliferate – Medscape

Posted: February 8, 2020 at 4:48 pm

New research results reinforce the benefits of quitting smoking.

Not only does it stop further damage to the lungs, it appears that it also allows new, healthy cells to actively replenish the lining of the airways. This shift in the proportion of healthy cells to damaged cells could reduce the risk for lung cancer, say researchers.

The findings were published online January 29 in Nature.

The team performed whole-genome sequencing on healthy airway cells collected (during a bronchoscopy for clinical indications) from current smokers and ex-smokers, as well as from adult never-smokers and children.

The investigators found, as expected, that the cells from current and ex-smokers had a far higher mutational burden than those of never-smokers and children, including an increased number of "driver" mutations, which increase the potential of cells to become cancerous.

However, they also found that in ex-smokers but not in current smokers up to 40% of the cells were near normal, with far less genetic damage and a low risk of developing cancer.

"People who have smoked heavily for 30, 40 or more years often say to me that it's too late to stop smoking the damage is already done," commented senior author Peter J. Campbell, PhD, Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom.

"What is so exciting about our study is that it shows that it's never too late to quit. Some of the people in our study had smoked more than 15,000 packs of cigarettes over their life, but within a few years of quitting, many of the cells lining their airways showed no evidence of damage from tobacco," he said. The comments appear in a press release issued by Cancer Research UK, which partly funded the study.

This study has "broadened our understanding of the effects of tobacco smoke on normal epithelial cells in the human lung," writes Gerd P. Pfeifer, PhD, at the Center for Epigenetics, Van Andel Institute, Grand Rapids, Michigan, writing in an accompanying comment.

"It has shed light on how the protective effect of smoking cessation plays out at the molecular level in human lung tissue and raises many interesting questions worthy of future investigation," he added.

Joint senior author Sam M. Janes, PhD, Lungs for Living Research Center, UCL Respiratory, University College London, United Kingdom, added that the study has "an important public health message.

"Stopping smoking at any age does not just slow the accumulation of further damage but could reawaken cells unharmed by past lifestyle choices," he said.

"Further research into this process could help to understand how these cells protect against cancer and could potentially lead to new avenues of research into anticancer therapeutics," James added.

In an interview with Medscape Medical News, Campbell said that the team would next like to try "to find where this reservoir of normal cells hides out while the patient is smoking. We have some ideas from mouse models and we think, by adapting the methods we used in this study, we will be able to test that hypothesis directly."

He continued: "If we can find this stem cell niche, then we can study the biology of the cells living in there and what makes them expand when a patient stops smoking.

"Once we understand that biology, we can think about therapies to target that population of cells in beneficial ways."

Campbell concluded that they are "a long way away yet, but the toolkit exists for getting there."

In their article, the team notes that the model explaining how tobacco exposure causes lung cancer centers on the notion that the 60-plus carcinogens in cigarette smoke directly cause mutagenesis, which combines with the indirect effects of inflammation, immune suppression, and infection to lead to cancer.

However, this does not explain why individuals who stop smoking in middle age or earlier "avoid most of the risk of tobacco-associated lung cancer."

They questioned the relationship between tobacco and mutagenesis. For two people who smoke the same number of cigarettes over their lifetime, the observation that the person with longer duration of cessation has a lower risk for lung cancer is difficult to explain if carcinogenesis is induced exclusively by an increase in the mutational burden, they mused.

To investigate further, the team set out to examine the "landscape" of somatic mutations in normal bronchial epithelium. They recruited 16 individuals: three children, four never-smokers, six ex-smokers, and three current smokers.

All the participants underwent bronchoscopy for clinical indications. Samples of airway epithelium were obtained from biopsies or brushings of main or secondary bronchi.

The researchers performed whole-genome sequencing of 632 colonies derived from single bronchial epithelial cells. In addition, cells from squamous cell carcinoma or carcinoma in situ from three of the patients were sequenced.

The results showed there was "considerable heterogeneity" in mutational burden both between patients and in individual patients.

Moreover, single-base substitutions increased significantly with age, at an estimated rate of 22 per cell per year (P = 10-8). In addition, previous and current smoking substantially increased the substitution burden by an estimated 2330 per cell in ex-smokers and 5300 per cell in current smokers.

The team was surprised to find that smoking also increased the variability of the mutational burden from cell to cell, "even within the same individual."

They calculated that, even between cells from a small biopsy sample of normal airway, the standard deviation in mutational burden was 2350 per cell in ex-smokers and 2100 per cell in current smokers, but only 140 per cell in children and 290 per cell in adult never-smokers (P < 10-16 for within-subject heterogeneity).

Between individuals, the mean substitution burden was 1200 per cell in ex-smokers, 1260 per cell in current smokers, and 90 per cell for nonsmokers (P = 10-8 for heterogeneity).

Driver mutations were also more common in individuals who had a history of smoking. In those persons, they were seen in at least 25% of cells, vs 4%14% of cells from adult never-smokers and none of the cells from children.

It was calculated that current smokers had a 2.1-fold increase in the number driver mutations per cell in comparison with never-smokers (P = .04).

In addition, the number of driver mutations per cell increased 1.5-fold with every decade of life (P = .004) and twofold for every 5000 extra somatic mutations per cell (P = .0003).

However, the team also found that some patients among the ex-smokers and current smokers had cells with a near-normal mutational burden, similar to that seen for never-smokers of the equivalent age.

Although these cells were rare in current smokers, their relative frequency was, the team reports, an average fourfold higher in ex-smokers and accounted for between 20% and 40% of all cells studied.

Further analysis showed that these near-normal cells had less damage from tobacco-specific mutational processes than other cells and that they had longer telomeres.

"Two points remain unclear: how these cells have avoided the high rates of mutations that are exhibited by neighbouring cells, and why this particular population of cells expands after smoking cessation," the team writes.

They argue that the presence of longer telomeres suggests they are "recent descendants of quiescent stem cells," which have been found in mice but "remain elusive" in human lungs.

"The apparent expansion of the near-normal cells could represent the expected physiology of a two-compartment model in which relatively short-lived proliferative progenitors are slowly replenished from a pool of quiescent stem cells, but the progenitors are more exposed to tobacco carcinogens," they suggest.

"Only in ex-smokers would the difference in mutagenic environment be sufficient to distinguish newly produced progenitors from long-term occupants of the bronchial epithelial surface," they add.

However, in his commentary, Pfeifer highlights that a "potential caveat" of the study is the small number of individuals (n = 16) from whom cells were taken.

In addition, Pfiefer notes that the "lack of knowledge" about the suggested "long-lived stem cells and information about the longevity of the different cell types in the human lung make it difficult to explain what occurred in the ex-smokers' cells with few mutations."

The study was supported by a Cancer Research UK Grand Challenge Award and the Wellcome Trust. Campbell and Janes are Wellcome Trust senior clinical fellows. The authors have disclosed no relevant financial relationships.

Nature. Published online January 29, 2020. Abstract, Comment

For more from Medscape Oncology, follow us on Twitter: @MedscapeOnc.

Read the original:
Stopping Smoking Allows Healthy Lung Cells to Proliferate - Medscape

Posted in Michigan Stem Cells | Comments Off on Stopping Smoking Allows Healthy Lung Cells to Proliferate – Medscape

First-of-its-Kind Bio-Artificial Pancreas on Track for Type-I Diabetes Cure – Global Trade Magazine

Posted: February 8, 2020 at 4:47 pm

Imagine a world where those living with Type 1 Diabetes, a chronic illness affecting more than 60 million adults globally, no longer had to deal with regular blood glucose monitoring, daily insulin injections or life-threatening nighttime hypoglycemic events, but instead could eat, exercise and sleep worry-free. Thats the kind of future an up-and-coming breakthrough technology is on track to creating.

Beta-O2 Technologies, a privately held biomedical company headquartered in Israel with research and industry affiliates across the U.S., is working to deliver a first-of-its-kind bio-artificial pancreas as a safe, effective and long-term cure for the disease. With preliminary animal trials showing promising results for its second generation breakthrough device, called Bio-artificial Pancreas (Air), the company is planning to begin human clinical trials within the year.

We have strong pre-clinical evidence to prove the safe operation of our device on animals, said Beta-O2 CEO Amir Lichter, noting that the second generation Air is performing well in ongoing animal studies. Its an enormous achievement that is paving the road for human trials.

Measuring approximately 2.5 by 2.5 inches, Air is made of titanium. It has two components: a macrocapsule that contains pancreatic cells and an oxygen tank equipped with an external port, so patients can easily refresh oxygen levels weekly. Once implanted under a patients skin, it becomes a natural source of insulin, sensing blood glucose levels and delivering insulin as required.

While there are a couple of other artificial pancreatic solutions being explored by different industry players, Beta-O2s disruptive technology is the only bio-artificial pancreas to incorporate an active oxygen supply, necessary to keep the pancreas cells in the implanted device functional and viable over the long term. Other solutions are demonstrating limited success because they rely on a patients bloodstream to deliver enough oxygen to keep the transplanted cells viable, which is problematic, Lichter explained.

Pancreas cells (islets) are extremely delicate, he said. We solve the problem by proactively supplying oxygen through an external source, providing a superior solution.

Lichter said the beauty of the Beta-O2 solution which holds 10 global patents for its exclusive immune protection capabilities and oxygen supply mechanisms is that its very generic, meaning it can contain cells from a human donor, cells from the pancreas of a pig, or cells derived in a lab from stem cells. Other advantages are that Beta-O2s bio-artificial pancreas does not require a patient to take intensive immunosuppression therapies after implant due to its protective encapsulation capabilities, and the device can quickly be retrieved from a patient if necessary due to malfunction or other health concerns, he explained.

Beta-O2 is currently collaborating with several U.S.-based pharmaceutical companies and academics, including researchers from Harvard University, MIT, University of Virginia and Cornell University, to further enhance the Air oxygen supply and its ability to measure glucose levels and secrete insulin once implanted. The company is also in negotiations to solidify its collaboration with several stem cell providers as it looks to secure an additional $15 million in investment funds to support its aggressive go-to-market strategy.

The active oxygen supply used by Beta-O2 is currently the best and most advanced technique for maintaining viability and function of large numbers of pancreaticislets (or stem cell-derived islets) in an encapsulation transplantation device, said Clark K. Colton ofthe Department of Chemical Engineering at MIT andBeta-O2 Scientific Advisory Board member.

Calling the Beta-O2 device a next-gen treatment option, Dr. Jos Oberholzer, Professor of Surgery, Biomedical Engineering and Experimental Pathology at the University of Virginia and Beta-O2 Scientific Advisory Board member, explained that after years of insulin injections and closed-loop insulin pumps and glucose sensors, patients will finally have access to a biological device solution to treat the most brittle forms of diabetes. The Beta-O2 device is the only implant that has shown reproducible results in humans with diabetes, with measurable insulin production originating from human islet cells within the device without the need for recipients to take any immunosuppressive drugs.

An earlier safety trial involving four patients in Sweden, supported by New York-based JDRF (Juvenile Diabetes Research Foundation), successfully demonstrated that Beta-O2s device is fully safe for use. No side effects were observed in patients who carried the device for up to 10 months, and the cells remained viable and functional.

Now, current animal trials underway at Beta-O2 are focused on extending the life of functional cells even further, with promising early results showing that rats implanted with Air are maintaining normal glucose levels.

With tangible evidence that we can maintain the viability and functionality of our cells for a long duration in rats, which have an immune system very similar to humans, we are looking forward to moving ahead with our second round of human clinical trials, Lichter said, noting that the company aims to be first to show that implanted biological pancreatic cells can successfully achieve normal blood sugar levels in diabetic patients without the need for immunosuppression therapy.

___________________________________________________________

About Beta-O2 Technologies Ltd. (www.beta-o2.com)

Beta-O2 Technologies Ltd. is a biomedical company developing a proprietary implantable bioreactor, the Air, for the treatment of Type 1 Diabetes. Air is designed to address the main problems of the otherwise successful procedures in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and limited functionality of the transplanted islets over time due to an insufficient oxygen supply. Beta-O2 investors include SCP Vitalife Partners, Sherpa Ventures, Aurum Ventures, Pitango Venture Capital, Saints Capital, Japanese and Chinese private investors.

See original here:
First-of-its-Kind Bio-Artificial Pancreas on Track for Type-I Diabetes Cure - Global Trade Magazine

Posted in Virginia Stem Cells | Comments Off on First-of-its-Kind Bio-Artificial Pancreas on Track for Type-I Diabetes Cure – Global Trade Magazine

Carol Vorderman says she could ‘burst with happiness’ as ‘every little pleasure’ makes her ‘grin’ – Mirror Online

Posted: February 7, 2020 at 2:44 pm

Carol Vorderman is one happy lady!

The 58-year-old telly star has taken to Twitter to share that's she's happier than ever, and could "burst" in a rather cryptic post.

Sharing the update with her 424k loyal followers, the former Countdown star asked:

"Ever been so happy you could actually burst?"

Carol then went on to gush about the fact she's feeling over the moon all the time, and hasn't had a down day for as long as she can remember.

She continued: "I'm feeling like that 7 days a week now....every little pleasure makes me grin... Always been a very happy soul, but it's like it's become ephemeral".

Fans speculated her message might have something to so with her love life, but Carol has since tweeted back to insist that's not true.

She wrote: "It was about being happy, and nothing to do with sex. Life's never dull eh?"

One told told the TV star: "You shouldn't hide your happiness just because social media is such a negative space."

While another quipped: "You deserve this happiness and even more. Don't shy away from sharing your joy with the world!".

It comes after Carol, who is usually notoriously secret about her love life, dropped some huge hints in a newspaper interview last year.

Carol, who is believed to be single, admitted she enjoys a very active sex life in an interview with the Daily Mail.

She said: "I get up to a lot of mischief. I have a number of special friends - but Im not doing anything wrong.

"Everyones single. And yes, apart from one, theyre all younger than me."

The mum to two grown children said that she will never reveal the names of who she is dating.

Carol also said she feels she deserves more "me time" after years of caring for others, including her beloved mum who passed away two years ago.

The former Countdown star also opened up about the benefits of her menopause medication - supplemented with testosterone and oestregen gels - which she claims has enhanced her bum and bust.

Carol said she takes the hormone replacement therapy alongside plant-derived natural bio-identical hormones.

She told reporters that this was the reason behind her gravity-defying figure and her increased libido.

Originally posted here:
Carol Vorderman says she could 'burst with happiness' as 'every little pleasure' makes her 'grin' - Mirror Online

Posted in Testosterone Replacement Therapy | Comments Off on Carol Vorderman says she could ‘burst with happiness’ as ‘every little pleasure’ makes her ‘grin’ – Mirror Online

AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure – BioSpace

Posted: February 7, 2020 at 2:43 pm

RESEARCH TRIANGLE PARK, N.C. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, and its NanoCor Therapeutics subsidiary today announced that the first patient has been dosed in a Phase 1 clinical trial of NAN-101. NAN-101 is a gene therapy that aims to activate protein phosphatase inhibitor 1 (I-1c) to inhibit the activity of protein phosphatase 1 (PP1), a substance that plays an important role in the development of heart failure.

Congestive heart failure (CHF) is a condition in which the heart is unable to supply sufficient blood and oxygen to the body and can result from conditions that weaken the heart muscle, cause stiffening of the heart muscles, or increase oxygen demand by the body tissues beyond the hearts capability.

"Dosing the first patient using gene therapy to target I-1c to improve heart function is a tremendous milestone not only for the AskBio and NanoCor teams but, more importantly, for patients whose quality of life is negatively affected by CHF, said Jude Samulski, PhD, Chief Scientific Officer and co-founder of AskBio. We initially developed this gene therapy as treatment for late-stage Duchenne muscular dystrophy patients who typically die from cardiomyopathy. Following preclinical studies, we observed that heart function improved, which led us to investigate treatment for all types of heart failure.

Were excited to be involved in this novel approach for patients with Class III heart failure, said Timothy Henry, MD, FACC, MSCAI, Lindner Family Distinguished Chair in Clinical Research and Medical Director of The Carl and Edyth Lindner Center for Research at The Christ Hospital in Cincinnati, Ohio, and principal investigator for the study. These patients currently have no other options besides transplant and left ventricular assist devices (LVAD). Today, we started to explore the potential of gene therapy to change their outcomes.

Heart disease is the leading cause of death worldwide, with CHF affecting an estimated 1% of the Western world, including over six million Americans. There is no cure, and medications and surgical treatments only seek to relieve symptoms and slow further damage.

Research by many investigators around the world has been trying to understand what exactly goes wrong in the heart and weakens its pumping activity until it finally fails, said Evangelia (Litsa) Kranias, PhD, FAHA, Hanna Professor, Distinguished University Research Professor and Director of Cardiovascular Biology at the University of Cincinnati College of Medicine. The aim has been to identify potential therapeutic targets to restore function or prevent further deterioration of the failing heart. Along these lines, research on the role of I-1c started over two decades ago, and it moved from the lab bench to small and large animal models of heart failure. The therapeutic benefits at all levels were impressive. It is thrilling to see I-1c moving into clinical trials with the hope that it also improves heart function in patients with CHF.

About the NAN-101 Clinical Trial NAN-CS101 is a Phase 1 open-label, dose-escalation trial of NAN-101 in subjects with NYHA Class III heart failure. NAN-101 is administered directly to the heart via an intracoronary infusion by cardiac catheterization in a process similar to coronary angioplasty, commonly used to deliver treatments such as stem cells to patients with heart disease. The primary objective of the study is to assess the safety of NAN-101 for the treatment of NYHA Class III heart failure, as well as assess the impact of this treatment on patient health as measured by changes in exercise capacity, heart function and other factors including quality of life.

AskBio is actively enrolling patients with NYHA Class III heart failure to assess three doses of NAN-101. Please refer to clinicaltrials.gov for additional clinical trial information.

Would you like to receive our AskFirst patient engagement program newsletter? Sign up at https://www.askbio.com/patient-advocacy.

About The Christ Hospital Health Network The Christ Hospital Health Network is an acute care hospital located in Mt. Auburn with six ambulatory centers and dozens of offices conveniently located throughout the region. More than 1,200 talented physicians and 6,100 dedicated employees support the Network. Its mission is to improve the health of the community and to create patient value by providing exceptional outcomes, the finest experiences, all in an affordable way. The Network has been recognized by Forbes Magazine as the 24th best large employer in the nation in the magazines Americas 500 Best Large Employers listing and by National Consumer Research as the regions Most Preferred Hospital for more than 22 consecutive years. The Network is dedicated to transforming care by delivering integrated, personalized healthcare through its comprehensive, multi-specialty physician network. The Christ Hospital is among only eight percent of hospitals in the nation to be awarded Magnet recognition for nursing excellence and among the top five percent of hospitals in the country for patient satisfaction. For more than 125 years, The Christ Hospital has provided compassionate care to those it serves.

About AskBioFounded in 2001, Asklepios BioPharmaceutical, Inc. (AskBio) is a privately held, clinical-stage gene therapy company dedicated to improving the lives of children and adults with genetic disorders. AskBios gene therapy platform includes an industry-leading proprietary cell line manufacturing process called Pro10 and an extensive AAV capsid and promoter library. Based in Research Triangle Park, North Carolina, the company has generated hundreds of proprietary third-generation AAV capsids and promoters, several of which have entered clinical testing. An early innovator in the space, the company holds more than 500 patents in areas such as AAV production and chimeric and self-complementary capsids. AskBio maintains a portfolio of clinical programs across a range of neurodegenerative and neuromuscular indications with a current clinical pipeline that includes therapeutics for Pompe disease, limb-girdle muscular dystrophy type 2i/R9 and congestive heart failure, as well as out-licensed clinical indications for hemophilia (Chatham Therapeutics acquired by Takeda) and Duchenne muscular dystrophy (Bamboo Therapeutics acquired by Pfizer). For more information, visit https://www.askbio.com or follow us on LinkedIn.

View post:
AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure - BioSpace

Posted in Ohio Stem Cells | Comments Off on AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure – BioSpace

How integrative medicine is changing the way cancer is treated – Fox Baltimore

Posted: February 7, 2020 at 2:41 pm

Cancer has an impact on every part of a patient's life. At GBMC Healthcare, the fight against cancer is about more than treating the disease. Delia Chiaramonte, M.D., Medical Director of Integrative and Palliative Medicine at GBMC, is leading the charge on integrative cancer care.

"It's not just about treating the cancer. It's also about how the person is coping, what side effects they may have from the disease itself or from the treatment, and how those symptoms make their life harder to manage," she says. "Treating the whole person is a really important part of cancer care."

These symptoms can be caused by a variety of internal and external sources, and Dr. Chiaramonte says it's important to get to the root of the cause of the symptom to better treat the patient.

"We hear the patient's symptoms then make an evidence-supported treatment plan that's different for every person, based on what their symptom is and why we think their symptom is happening," she explains.

For example, one person may not be sleeping well because of a physical reaction to chemotherapy. Another may not be getting good sleep because their mind is filled with anxious thoughts about their diagnosis.

Dr. Chiaramonte says there are three main causes of symptoms, and the Integrative Medicine Program makes it easier for patients to get an evidence-based, effective treatment plan and to receive those treatments at the Sandra & Malcolm Berman Cancer Institute at GBMC.

"We pull out all the causes and then address them with the treatment that is likely to work on that particular person, and often it's not just one cause," she explains.

The mind-body connection

The sympathetic nervous system directs our body's "fight or flight" response, which can be caused by both external factors and our own thoughts.

"Because the mind and body are connected, our anxious thinking can generate the 'fight-or-flight' response, and that can result in all kinds of physical symptoms, including increased pain, palpitations, changes in GI function, sleep, and nausea," Dr. Chiaramonte says.

According to Dr. Chiaramonte, there are a variety of ways to help decrease the sympathetic nervous response system, including craniosacral therapy (a light-touch manual therapy technique that works to balance and facilitate healing in the body) and massage. These methods reduce patients' anxiety.

Cancer treatment symptoms

It's no secret that chemotherapy and radiation can be taxing on the body. Nausea, fatigue, and neuropathy (nerve pain caused by damaged nerves) are just some of the side effects of cancer treatments that integrative modalities can help alleviate.

"Some energy medicine has been shown to help chemo-induced peripheral neuropathy," Dr. Chiaramonte says. "Many people come in with fatigue, usually from a combination of poor sleep and treatments. Acupuncture, meditation and guided imagery, reiki (a stress reduction and relaxation technique involving a trained practitioner), and yoga have all been shown to help fatigue."

Physical pain

Dr. Chiaramonte reiterates that the Integrative Palliative Medicine Program is just that: an integrative medicine program and not an alternative to standardized cancer care.

"I treat pain with medicines, with different kinds of opiates and complementary medications," she says. "But acupuncture has been shown to decrease pain. Meditation and guided imagery have been shown to decrease pain. Reiki has been shown to decrease pain. Depending on the person, we may use multiple modalities to help them manage their pain."

Massage is also an oft-used modality for physical pain.

"Often, when something hurts in our body, the muscles around it contract and tighten to try to protect it, and over time it can become the actual contraction of the muscle that hurts, not necessarily the underlying factor," Dr. Chiaramonte says.

She explains this can also tie into the mind-body connection because "if you're generating a lot of anxious thinking, you're more likely to continue to have this muscle tension, and massage can help."

Integrative treatment plans will vary by patient, which Dr. Chiaramonte says is the key to taking care of the mind, body, and spirit of every individual.

"We find out the 'why' behind each patient's symptoms, pull out the causes, and then come up with a plan for that particular patient, using all the tools that work."

For more information Integrative Medicine at GBMC HealthCare, click here.

Originally posted here:
How integrative medicine is changing the way cancer is treated - Fox Baltimore

Posted in Integrative Medicine | Comments Off on How integrative medicine is changing the way cancer is treated – Fox Baltimore

More Than Chemo: A Different Way to Treat Cancer – Next Avenue

Posted: February 7, 2020 at 2:41 pm

People facing a cancer diagnosis, particularly a late-stage cancer diagnosis, may feel that their locus of control over life has been removed. They are now patients, relying on their oncologist, surgeon, radiation therapist and nursing staff.

But, consider an integrative cancer approach in which patients feel more empowered by an assortment of options they can choose, such as changing their diet, exercise, incorporating methods for reducing stress, seeing an acupuncturist and engaging in mind-body practices. Proponents of an integrative approach say these complements to conventional treatment (chemotherapy, radiation, surgery) make treatment more effective while reducing side effects.

Many cancer patients, like Jasmine Guha-Castle, are turning to integrative cancer care to enhance quality of life, improve outcomes and possibly beat the odds.

Guha-Castle, 50, of Austin, Texas, wont slow down for a minute in her fight to beat breast cancer, again. She made healthy living and volunteering at animal shelters her lifes mission since she overcame breast cancer 13 years ago.

But she received the unfortunate news that her breast cancer had returned while heading to England two summers ago. This time, it was metastatic, meaning the kind that spreads. And it was triple negative, a more aggressive kind of cancer that will not respond to hormonal therapy medicines. So, she flew right back to Austin.

This place gives me hope, which the other places havent so far.

Early in her treatment, regardless of a chemotherapy day, Guha-Castle could be found swimming in Austins Barton Springs pool, attending a meditation class, visiting a nutritional oncologist or acupuncturist, making carb-free foods, dancing and most often, reading science-based information about triple-negative breast cancer (TNBC).

Where you wouldnt find Guha-Castle was hanging out with other patients just because they share her condition. That isnt my cup of tea, says the expat Brit, who finds it hard to connect with members of the cancer community if they are depressed and not optimistic like she is.

You have to be positive and proactive to change the environment of your cells, notes Guha-Castle.

There are more options if you have the right doctor, she says. Initially, she was only treated with chemotherapy and radiation by oncologists who use conventional treatment methods. She says traditional oncologists did not show an interest in hearing about her anti-cancer literature related to medicinal mushrooms, turmeric pills and other approaches that might improve outcomes and help her feel better. She also wanted more guidance, more personalized care and more hope.

Integrative oncology is not alternative medicine, which usually refers to treatments used instead of traditional ones. It also isnt it only complementary, which refers to the use of single-intervention add-ons to support mainstream treatment. So, what exactly is integrative oncology?

Here is a comprehensive definition from JNCI (Journal of the National Cancer Institute) Monographs: Integrative oncology is a patient-centered, evidence-informed field of cancer care that utilizes mind and body practices, natural products and/or lifestyle modifications alongside conventional cancer treatments. Integrative oncology aims to optimize health, quality of life and clinical outcomes across the cancer care continuum, and to empower people to prevent cancer and become active participants before, during and beyond cancer treatment.

After reading about cancer programs at different clinics, Guha-Castle decided to fly to the independent Block Center for Integrative Cancer Treatment in Skokie, Ill. She was reinvigorated by the clinic, with all of its physicians and specialists in the same building.

A growing number of leading U.S. cancer care centers claim to have integrative medicine programs.

Guha-Castle found it to be like no clinic she had seen, with a kitchen for nutrition classes, a yoga and exercise area and soothing lighting and music. Exercise equipment was only steps away from the chemotherapy areas.

This place gives me hope, which the other places havent so far, she says.

She was particularly motivated after reading the Block Centers preliminary study of stage IV breast cancer patients who were treated there. The treatment improved survival time for the patients, generally, compared to patients treated at conventional clinics.

Dr. Keith Block is the Block Centers medical and scientific director, and considered to be the father of integrative oncology. He developed a treatment program called Life Over Cancer, which uses a plant-based diet, exercise, nutritional supplements, nutritional infusions (administered intravenously) and mind-body therapies. He also uses innovative methods of chemotherapy and experimental and off-label medications.

No two patients are treated in the same way there. Treatment is based on individualized testing to determine a persons biochemical environment or internal biochemistry. This is the environment surrounding a persons cancer cells that can influence the growth and spread of cancers. It includes levels of inflammation, oxidation and the state of his or her immune system. Block uses blood tests for this assessment, which he calls this terrain testing or taking a blood terrain panel.

At the Block Center, all conventional cancer treatments, physician visits, blood draws and visits with counselors are covered by Medicare and most private insurance plans. Some extras, like dietitians, nutritional supplements and nutritional infusions are out-of-pocket.

Fortunately for Guha-Castle, she can afford to fly to the Block Center every two weeks for treatment. But many people dont have the means to do that, she acknowledges. She is still associated with an oncologist in Austin for blood transfusions and scans, but she says she would rather pay more to get the kind of care she wants at the Block Center.

A growing number of leading U.S. cancer care centers claim to have integrative medicine programs.

Dr. Lorenzo Cohen, professor and director of the Integrative Medicine Center at the University of Texas MD Anderson Cancer Center in Houston, says what distinguishes his clinic from the Block Center is being part of an academic medical system. He says blood testing and prescribing medications, particularly of herbs and supplements, becomes a little more challenging when you are in an academic medical center and must follow strict evidence-based guidelines, such as the National Comprehensive Cancer Network guidelines.

Treatments provided by integrated programs within large cancer centers are led by physicians, who also work with providers to guide patients in services like acupuncture, massage, music therapy, yoga, Tai chi and qi gong (methods of movement, breathing and meditation), physical therapy, nutrition and health psychology throughout treatment and whenever possible.

Like other treatment programs, they take commercial insurance and Medicare for standard procedures. The Centers for Medicare and Medicaid Services now covers acupuncture for Medicare patients with back pain. Cohen says this shows that insurers see that integrative approaches are not only cost effective, but a huge value gained in quality of life.

Dr. Dawn Mussallem specializes in breast care at Mayo Clinics Integrative Medicine and Health program in Jacksonville, Fla. She worked with Cohen on an expert integrative oncology panel that recently endorsed the Society for Integrated Oncology Breast Cancer Guidelines.

In the last couple of years, Mussallem developed and piloted a breast-specific integrative medical program within Mayos Jacoby Center for Breast Health that included acupuncture, massage therapy, cancer nutrition, mindfulness classes, yoga and superfood cooking classes.

Mussallem met with patients about whole-person well-being, discussing aspects like nutrition, exercise, purposeful living and avoidance of toxins like alcohol and tobacco. The programs results showed a favorable patient benefit on quality of life, and these integrative services are now offered to all cancer patients at Mayo Clinic in Jacksonville.

Given the high prevalence of patients using alternative modalities often driven by misinformation available to patients, there is a strong need to guide the use of appropriate integrative oncology care to achieve optimal outcomes for our patients, Mussallem says.

Next Avenue brings you stories that are inspiring and change lives. We know that because we hear it from our readers every single day. One reader says,

"Every time I read a post, I feel like I'm able to take a single, clear lesson away from it, which is why I think it's so great."

Your generous donation will help us continue to bring you the information you care about. What story will you help make possible?

Next Avenue - 2020. All rights reserved.

See the original post:
More Than Chemo: A Different Way to Treat Cancer - Next Avenue

Posted in Integrative Medicine | Comments Off on More Than Chemo: A Different Way to Treat Cancer – Next Avenue

Cannabis and integrative medicine in Canada – Health Europa

Posted: February 7, 2020 at 2:41 pm

Dr Dani Gordon is a double board-certified medical doctor, working with integrative medicine, as well as wellness expert and leading expert in clinical cannabis/cannabinoid medicine after treating 2500+ patients in Canada in a referral complex chronic disease practice where she specialised in neurological disorders, chronic pain and mental health conditions.

She speaks internationally on cannabinoid medicine and in mid-2018 moved to London to train the UKs first cannabis medicine specialist physicians, developing a leading online cannabis medicine physician training programme, helping to set up the UKs first cannabis medicine clinics and become a founding member of the UK Medical Cannabis Clinicians Society (MCCS), delivering the MCCS guidelines to 10 Downing Street.

Gordon is an American Board Specialist in Integrative Medicine, the newest American sub-specialty of mainstream medicine, focussed on the intersection of conventional and natural evidence-based medicine and therapeutics and she has studied herbal medicine and meditation extensively throughout India and south east Asia with traditional teachers, mind-body medicine at Harvard, neurofeedback brain training and EEG brain imaging techniques with leaders in the field in North America.

Here, she speaks to Health Europa Quarterly about her extensive background in cannabis medicine, patient experience, and the representation of women in the rapidly evolving industry.

I am medical doctor and Im trained in both integrative medicine, which is natural evidence-based medicine and a recognised speciality. I am also trained in family medicine in Canada, and I specialise specifically in herbal medicine, cannabinoid medicine as part of my integrative medicine practice.

I have been practising integrative medicine for the last decade in Canada and that is mostly what I do in my clinical practice. Around four years ago, I started experimenting with medical cannabis and I have been running a complex chronic disease clinic with a focus on medical cannabis for the last four years in Canada; at this point I have treated thousands of patients using medical cannabis and CBD.

I have also trained medical students, physicians and allied health care providers on how to use cannabis medicine. I am a writer, and I speak worldwide on cannabis medicine and other natural evidence-based medicine topics and integrative medicine. Last year I relocated back to the UK where Im also a citizen to get involved on this side of the pond.

Since that time, Ive been involved in quite a few major projects here, I advise on some of the high profile child epilepsy cases, and Im the vice chair of the Medical Cannabis Clinicians Society. I advise companies and I have overseen training the first group of UK specialist doctors in cannabis medicine along with overseeing the curriculum for the Academy of Medical Cannabis, which is the main body established to educate physicians and researchers on medical cannabis.

Integrative medicine is a subspecialty which started out in the States. I already had my postdoctoral fellowship and you already need to be a doctor to take the fellowship programme. Its a two-year fellowship which I completed in 2012 in the US, and the reason I decided to do it is because I was practising as a holistic medical doctor in Canada. I was already a conventionally trained medical doctor with the qualifications I had, but I wanted to add to my practice natural things such as herbal medicine, mindfulness-based stress reduction techniques and mind- body techniques for the benefit of my chronic disease patients.

I went to the states and completed this training in 2012, because there was no postdoctoral level training in natural medicine and I really wanted to have the most bona fide qualification. Since 2012, it has now become a fully recognised speciality in medicine in the US. Initially I wasnt interested in integrative medicine when I started my practice in 2009 as a family doctor helping people with chronic disease was my main interest. I realised that just using pharmaceutical drugs alone for complex chronic diseases, were not really cutting the mustard so to speak. It just wasnt really working very well for a lot of my patients with anxiety, stress related disorders, mental health conditions, fibromyalgia, chronic fatigue syndrome, chronic pain and sleeping problems. Pharmaceutical drugs were just not helping enough on their own.

I became interested in cannabis specifically in 2015. At that time, I had been practising with herbal medicines and conventional drugs for almost half a decade. A lot of my patients started to tell me about their experiences with using cannabis therapeutically because I practised herbal medicine as well as the conventional kind.

I was really interested in the things they were doing, for example some of my patients were juicing cannabis in its raw form and saying that it didnt make them feel high. They explained that it was really a health supplement that their parents generation had been using it in West coast Canada where a lot of people grow cannabis on their land. That got me really interested in why they were juicing it and not getting high and what was what was happening with this plant; as a herbalist I became very intrigued.

I also had a few patients who were at the end of their life with terrible cancers and they told me how they were taking homemade cannabis tinctures to help reduce their morphine needs so that they could be more aware and alert. It allowed them to manage their pain, experience better quality of life and spend more time with their families in their final days.

I started to investigate it from there to find out how I could introduce it into my practice, so people wouldnt need to experiment with it alone and in isolation. I sought out additional training in cannabis medicine, and just found a few mentors but back in 2015, there really wasnt that much awareness. I started opening my door to cannabis medicine being included in my practice through the Health Canada legal system and I just started learning hand in hand with my patients. I was reading all the latest research and working with the plant just as I did with all my other herbal medicine practise. I started to see all these incredible changes in my patients so that really spurred me on to continue.

When I first started out in cannabis medicine, I was actually quite sceptical because I had a lot of ingrained training from medical school that cannabis was an addictive drug that it was going to make people lazy, hurt their brains and make them more tired.

What I found was the patients who were in orphan disease categories with conditions such as fibromyalgia, chronic fatigue syndrome, chronic anxiety and chronic depression, chronic pain were improving when nothing else we had tried previously was really effective. When I started to study the endocannabinoid system, which is the cannabis system we have in our own bodies It made sense because essentially the cannabis plant regulates our own cannabis system which is involved in processes such as regulating our mood and pain signals.

We [doctors and researchers specialising in cannabis medicine] think that a deficient endocannabinoid system also known as Endocannabinoid Deficiency Syndrome theory may play a role in all of these overlapping symptom clusters that are very, very difficult to treat. Conditions such as irritable bowel syndrome, fibromyalgia, chronic daily headaches, chronic migraine, chronic depression and anxiety all these issues sometimes improve using traditional drugs, but it usually doesnt provide a good solution with few side effects.

What I started to do with cannabis is adding in different forms of cannabis medicines primarily the low THC and high CBD strains of the plant and then selecting different strains of the plant more specifically. I found with my background as a herbalist I was able to really personalise the therapy.

With many of my patients who suffered from chronic mental health conditions, I really wanted to get them practising something called Mindfulness Based Stress Reduction (MBSR) which I went to Harvard to study alongside some of the top researchers in the world. I really believe in it; however, it is not a quick fix. Unfortunately, people with chronic pain and chronic mental health conditions are often so poorly that they cant summon the mental effort to keep the practise going long enough for it to start working.

Once I got them onto cannabis, even the low THC cannabis which did not make them feel high, I started to get them to use it before their mindfulness or meditation practise. I found that they started to do more mindfulness and from there they started to exercise more because they werent fatigued. Many patients started to lose weight and become more social; it was kind of a snowball effect that allowed them to do a lot of other things. It allowed them to engage with a lot of non-drug therapies such as CBT that they couldnt engage with before because they were too ill.

I think its been enormously important to the patient experience and I have to say that it has reinvigorated my love of medicine in many ways. It is the kind of medicine that is very well tolerated by most people and helps them with their quality of life so greatly, even though it doesnt cure their condition.

We dont know that cannabis cant cure things and maybe one day we can figure that out, but for now its about quality of life. It has changed my patients lives in ways I could never imagine. Nobody Ive ever prescribed an antidepressant to has ever said to me this has changed my life, but daily and weekly in my practice, I get letters from patients and verbal testimonials that starting them on cannabis has saved their marriage, or completely changed the relationship they have with their children because they can engage with their family life again.

I have seen patients who were so debilitated by very advanced arthritis that they couldnt work or play music anymore and they are able to go back to those things. I had one patient who surprised me with a concert; he hadnt played in 10 years and he was very depressed because his hands were so painful.

I have seen ranchers who live out in the middle of the countryside in Alberta who couldnt get on their horse anymore to round up their cattle and when I did a follow up consultation via a video app, they took me with them on a ranch ride for the first time in five years. It had been five years since theyd been on the horse.

Ive treated young adults with epilepsy who had been told that they would never be independent and that they were going to be in a care home for the rest of their lives, and seen them be able to go to a part time job and get an animal to keep them company these things were not possible before. It changes the whole familys lives not just the person with epilepsy. As far as a single thing I can give someone, although its not a cure it has been the single most powerful tool that I have found so far since going from a Western medicine doctor to a herbal medicine doctor.

One of the things that I get very excited about is changing the perception of cannabis because I think the old perception of cannabis was this kind of stoner culture. On the recreational side of cannabis, which is very different to the medical side. Its not a very wholesome image.

The images that were portrayed of women were often women in bikinis smoking cannabis which are not necessarily positive images of women in general and definitely not the image of cannabis the medicine as I practise it. I feel very lucky to be involved in kind of seeing the transformation of the image of the plant because a hundred years ago, it was a perfectly respectable botanical medicine and its coming full circle back to that.

I feel that women have played a large role in that to be honest, and really introducing a balanced movement into the modern era. It isnt just me, there is Hannahs Deacon, Alfies mother and Charlie Caldwell these are the women who have had kids with epilepsy and have had to fight for access to the treatment. Carly Barton is a good friend of mine and a patient advocate. I have needed and developed a network of women and through social media many of them have become my friends. I think it has been a powerful tool for connecting and empowering women.

One thing that you do find when you enter the business side of the cannabis world is a lot of the people may have come from a traditionally male dominated industry. Often, when I go to give a talk, I will be one of the only women there, but I do feel that is already changing. It is certainly the case that as with many male dominated, corporate professions, women are generally underrepresented which is something needs to be taken seriously; we might potentially have to work harder than men.

Dr Dani GordonIntegrative Medicine Specialistdrdanigordon.com

Please note, this article appeared in issue 11 ofHealth Europa Quarterly, which is available to read now.

Read the original post:
Cannabis and integrative medicine in Canada - Health Europa

Posted in Integrative Medicine | Comments Off on Cannabis and integrative medicine in Canada – Health Europa

Finding Chemo – National Pain Report

Posted: February 7, 2020 at 2:41 pm

I wont sugar coat it. Fighting breast cancer with chemo is a nightmare.

After three infusions, Ive grown accustomed to the weekend fatigue that will barely allow me to leave my couch. On infamous Chemo Day 3, after being up all night with aimless energy and a racing mind, I literally feel like Im going crazy, as if Im a stained-glass window thats been shattered and I cant quite figure out how to put the pieces back. The doctors refer to this symptom as steroid induced psychosis. Im trembling, dizzy and dropping things. My spirit and joy for life are almost non-existent as I generally feel flat-lined emotionally. Being nauseous and rapidly going bald round out the experience. You get the picture.

On a positive note, my pain remains in check after a fear-inducing first week. With my initial infusion came a CRPS-like symptom known as myalgia. For several days my legs would get unbearably achy before amping to up-all-night, think-Im-gonna-die pain. Terrified, I made an emergency appointment with my integrative doctor and Dr. Taws reassuring nature and acupuncture treatment calmed my mind and body. As always, integrative medicine is my best healer and my new chemo-induced pain symptom is gone.

Cynthia Toussaint

Im happy to report that despite the trauma of chemo, all is progressing well. That being said, Im certain that Im suffering far more than need be due to the over-care of western medicine. This has always been my complaint with pain care and now with cancer treatment, its the same damn thing. Truth be told, I think western medicines doing the cancer thing completely backassward. Theyre making us patients suffer far more than necessary. Its called over-care and its all about the blessed buck.

I got the first whiff of profit-motive after I had my port surgery (an implantable device that provides a direct line to the artery) a procedure that blew up my CRPS so badly I strongly considered not following through with the chemo. After somehow surviving six days of hell, my infusion nurse on intake asked me why on earth I had a port. For these drugs, Cynthia, we just go through the arm. Stunned, I asked my doctor if this was true as hed told me the port was non-negotiable. Chagrined, Dr. Lewis admitted to the deceit, but with the rationale the port is much easier for access. Sadly, my port isnt working well, needing multiple flushings to clear it. And it may stop working altogether.

Another big money maker for this healthcare system happened when I arrived for my first infusion. After doctor appointments, procedures and preps, a nurse casually mentioned theyd forgotten to do a kidney work up and wouldnt be able to start that day. I got the sense that this kind of screw up wasnt uncommon. All I could think about was how much money theyd just made off of me and absolutely nothing got done.

And then there are the many expensive, unnecessary drugs. Before each infusion I get zonked with enough meds to kill a small donkey. In fact its the steroid and Benadryl delivered by IV that make me most miserable through the week. These drugs are supposedly given to fend off an allergic reaction to the chemo. But when no reaction happens, Dr. Lewis keeps me at the same levels. Angry and suffering, I pushed him to lower both doses and allow me to take them orally. He finally acquiesced, and the crazies have tempered. Next round, Ill be pushing hard to go down all the way. Far fewer bucks in their pocket, but, thankfully, far less suffering for me.

Another suspicious money maker is the plethora of anti-nausea meds theyre plying me with. One, aprepitant, is doing the job, probably too well, at almost $3000 a pop. When I talked to Dr. Lewis about having so little nausea Hey, can we go down?- rather than decreasing the aprepitant, he pushed me to take preventative anti-nauseas through the week. Again, hes medicating a symptom thats not plaguing me. Oddly when I told him that I wasnt taking the additional Rxs, he refused to remove them from my records. Think about it. Data gleaned from my chart will help sell drugs that Im not taking, but are deemed successful.

On the integrative front, its just not happening with my infusion center, one known for this progressive care approach. Dr. Lewis is kind and smart, but to my disappointment, he basically dismissed my plan to exercise, work, eat a cancer fighting diet, meditate, get sleep, etc. to enhance chemo efficacy. He applauded my motivation, but has never followed up. When I asked about his experience using acupuncture for cancer patients, he mentioned knowing a doctor in med school once who had tried it. Frankly, I was stunned at his ignorance.

At the infusion center, its more of the same. I find it nonsensical that the nurses want fitness tips from me, the patient and, in fact, Im helping several of them with their exercise and diet. Then when I was offered a snack, an assortment of chips and soft drinks, they almost did a double-take when I politely declined their junk food, asking for fruits and nuts instead. Still, Im bonding with these super nice women who seem genuinely pleased that I question my doctors and have taken the leadership role of my care.

Due to my CRPS, I educated myself for six months before choosing which cancer treatments to take, with whom and where. At Dr. Taws strong suggestion, Im going low and slow with the chemo. Instead of getting a big blast every three weeks which is the traditional method, I do a third of a dose weekly. This regimen affords me fewer side effects with far more efficacy. And perhaps more importantly, it greatly lowers the chance of me getting more high-impact pain in the way of neuropathy and bone pain. I feel in control or, at least, Im getting there. I feel empowered.

I thought cancer care, because of its advanced standing as a measurable disease and mountain-high level of funding, would be light years ahead of pain treatment. But I couldnt have been more wrong. In fact Im more aware than ever, that out of necessity we women in pain have had to find our own outside-the-box pain remedies, and these inventive, integrative strategies lead to healing and well-being. My 37+ years of being a critically-thinking pain warrior are serving me beautifully with cancer. More to the point, they could be saving my life.

With every new diagnosis, we must avoid panic, follow our guts, get educated, ask questions, choose our health care practitioners with utmost care and trust and, most importantly, take responsibility for our own wellness.

Spoiler Alert: By finding chemo my way, a miracle has happened. Ill share the good news in my next post

See the rest here:
Finding Chemo - National Pain Report

Posted in Integrative Medicine | Comments Off on Finding Chemo – National Pain Report

Page 1,147«..1020..1,1461,1471,1481,149..1,1601,170..»